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I Aim of this report 
This rapid communication provides an update on drug-
related hospital emergency presentations in Europe with  
a specific focus on the latest results for acute drug toxicity 
presentations to the European Drug Emergencies Network 
(Euro-DEN). The Euro-DEN network was established in 
2013 as a European Commission DG Justice funded 
project with the aim of improving knowledge at a European 
level on acute established illicit/recreational drug and new 
psychoactive substance (NPS) toxicity. The project has 
continued as the Euro-DEN Plus project since the 
European Commission funding for the original Euro-DEN 
project ended in April 2015.
This report is primarily based on presentations and 
discussions at a two-day meeting of the Euro-DEN Plus 
network in Lisbon on 7 and 8 April 2016. The meeting 
provided a platform for the presentation of new analyses 
from the Euro-DEN dataset, and further development and 
analyses of the Euro-DEN project were also discussed. 
Data presented here relate to analysis of acute drug 
toxicity presentations to the 16 original sentinel centres in 
the Euro-DEN network for the first two years of data 
collection (October 2013 to September 2015). This review 
also includes highlights from the new findings discussed 
during the meeting and consideration of the further 
development of the work of the Euro-DEN network and the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) in this field. It should be noted that as this 
publication is, in part, based on the presentations to the 
meeting, some of the information outlined here is 
necessarily preliminary.
While the data do not necessarily provide a nationally 
representative picture, as only selected sites are included 
from participating countries, using a number of sentinel 
sites in significant locations provides useful information on 
the types of drug involved in presentations to emergency 
services in Europe, and the trends at these sites.
Hospital emergency data can provide a unique insight 
into acute health harms related to drug use, although at 
present there is limited systematic data collected on 
acute drug toxicity in Europe.
Euro-DEN Plus is a sentinel monitoring system of 
hospital emergency services that currently provides 
data on acute drug toxicity from 20 sentinel sites in  
14 countries.
There were a total of 10 956 presentations to the  
16 original sentinel Euro-DEN Plus centres over the 
two-year period October 2013 to September 2015.
Opioids and heroin were the drugs most frequently 
associated with acute drug toxicity presentations at 
emergency departments. Over the two-year period 
heroin was the most common drug and was involved in 
2 604 (24 %) of the presentations.
Cocaine and cannabis were also prominent with, 
respectively, 1 806 (16 %) and 1 741 (16 %) 
presentations where these drugs were involved.
New psychoactive substances (NPS) were, 
comparatively, much less commonly reported, seen in 
11 % of presentations over the two-year period.  
The most frequently seen NPS were cathinones, in 
particular mephedrone.
Alcohol and prescription medicines were frequently 
observed in acute drug toxicity presentations — the 
most common prescription medicines implicated were 
benzodiazepines and opioids.
Polydrug use (defined as two or more drugs other than 
alcohol involved in the presentation) was reported in  
38 % of presentations; overall, the mean number of 
drugs per presentation was 1.6.
Three-quarters (76 %) of the presentations were in 
males, and presentations were most common among 
those aged 20–39.
Most patients (76 %) were discharged directly from the 
emergency department, and almost half (45 %) were 
discharged within four hours.
Cases with acute drug toxicity can constitute a burden 
on emergency health services. Agitation and aggression 
are common features, and presentations are more 
common at weekends, late evenings or night.
At a glance: a summary of key points 
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I Background 
Despite the potential for the use of illicit drugs and NPS to 
cause significant morbidity and mortality, there is currently 
limited systematic data on acute drug-related harm 
available in Europe (Heyerdahl et al., 2014) beyond data on 
drug-related infectious diseases, drug-related deaths 
(overdoses) and treatment.
However, a unique insight into acute health harms related 
to drug use is provided by hospital emergency data, which 
broaden the scope and potential impact of monitoring the 
health consequences of drug use, as detailed in a previous 
EMCDDA review (EMCDDA, 1999). Emergency data can 
serve a number of purposes along two main axes: both as 
a routine drug-trend monitoring tool, and as an early 
warning/signalling tool.
With regard to this epidemiological monitoring function, 
emergency data may act as an indicator of high-risk drug 
use trends (namely numbers, age and gender of cases with 
acute drug toxicity related to the most frequent drugs 
— heroin, cocaine, cannabis and amphetamine — and also 
the misuse of prescription medicines). This is also a source 
of information on harms among certain sub-populations of 
drug users (e.g. crack cocaine users, NPS users). 
Emergency data can also provide information on the 
serious consequences of drug use (e.g. fatal and near-fatal 
toxicity, drug-related psychosis), and on specific 
substances (e.g. case series of acute cannabis toxicity 
(Dines et al., 2015)). Finally, data from emergency settings 
can be used as a source for capture-recapture studies 
aiming to estimate prevalence (Domingo-Salvany et al., 
1998; Espelt et al., 2015). The potential of this data to 
complement other, more established indicators on the 
drug situation has been explored in several reports and 
papers (EMCDDA, 2014; Heyerdahl et al., 2014;  
Mena et al., 2013; Wood et al., 2014) (1).
In terms of providing an early warning function, hospital 
emergency data are useful for detecting and monitoring 
new patterns of use or misuse of substances (such as 
NPS), as a source on new trends related to established 
drugs, for example new epidemics in heroin toxicity.  
Data from emergency settings may also contribute to early 
warning systems, as they often capture signals earlier than 
other monitoring systems based on mortality or treatment 
data.
(1)  See more information, expert presentations, other outputs such as 
videos, and publications on cocaine and benzodiazepines at  
http://www.emcdda.europa.eu/topics/pods/cocaine-related-emergencies 
and http://www.emcdda.europa.eu/topics/pods/benzodiazepines. 
Guidelines in several languages are also available from  
http://www.emcdda.europa.eu/activities/emergencies
A review of the monitoring of drug-related acute 
emergencies, including an analysis of cocaine-related 
emergencies in 30 European countries, was published in 
2014 (EMCDDA, 2014). This Europe-wide review revealed 
that while many countries can report some basic, routine 
surveillance data from hospital emergencies and/or 
hospitalisation, these tend to be limited to the main drugs 
(heroin, cocaine, cannabis) and few countries have set up 
enhanced monitoring systems. The review notes that the 
Drug Abuse Warning Network (DAWN) in the United States, 
which ran for many years until its closure in 2011 (2), 
provided a model for hospital emergency surveillance 
systems in some European countries.
While routine monitoring of drug-related emergencies 
exists in some countries, it has a number of limitations,  
in particular a significant underestimation of cases, due 
mainly to problems with the coding systems used at  
a hospital level for acute drug toxicity presentations  
(Shah et al., 2011; Wood et al., 2011).
With a view to addressing the paucity of available data on 
acute drug toxicity, the Euro-DEN group designed and 
implemented a ‘sentinel’ centre model to collect data on 
acute drug and NPS toxicity presentations to emergency 
departments in Europe in a systematic way.
From a European monitoring perspective, the sentinel 
network allows cross-checking of local emergency data 
with other indicators, such as prevalence of use, mortality, 
treatment demand, and market data including seizures and 
purity of the drugs. It can also contribute to the rapid 
information function of the EMCDDA (through 
contributions to ‘Trendspotter’ surveys and to the EU Early 
Warning System), with its capacity to provide reports of 
acute toxicity involving NPS.
More information on EMCDDA activities in the drug-related 
hospital emergencies area is available from  
http://www.emcdda.europa.eu/activities/emergencies.
I Euro-DEN methods of data collection 
The Euro-DEN group developed a minimum dataset to 
capture the key demographic, clinical and outcome 
variables in presentations with acute drug and NPS toxicity 
to emergency departments. A network of sentinel centres 
with a specialist clinical and research interest in acute 
drug toxicity was developed (Figure 1) and these centres 
collect data using the Euro-DEN minimum dataset on all 
(2)  http://www.samhsa.gov/data/emergency-department-data-dawn/about
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acute drug toxicity presentations to their emergency 
department (Wood et al., 2014).
A Microsoft Excel spreadsheet was created using pre-
formatted variables and drop-down menus where possible 
to ensure consistency in the collection of the minimum 
dataset. In the first year of data collection 58 variables 
were collected; this was refined for year 2, with the number 
of data variables cut to 43 — this represents the final 
Euro-DEN Plus minimum dataset. Data variables no longer 
collected include those in which there is often limited 
information available (for example, the dose and route of 
drug administration) and those that were particularly 
time-consuming to collect and were felt to be less 
important to the overall picture of drug-related harm (for 
example, electrocardiogram and biochemical parameters).
Each centre obtained appropriate local ethical approval 
from their institution for the collection of the data. The 
recording of the drug(s) involved in the presentations is 
based on the patient’s self-report and/or the clinical 
interpretation of the drugs used by the clinicians managing 
the patient and collecting the Euro-DEN data in each 
centre. If drug screening is undertaken as part of routine 
clinical care the results of the screening are collected, but 
analysis is not specifically undertaken for the project.  
This is representative of international best practice in the 
management of acute drug toxicity where patients are 
treated on the basis of the clinical pattern of toxicity and 
the self-reported drugs used, rather than on the basis of 
analytical confirmation of the drug(s) detected.
Inclusion criteria: Presentations are included if they 
have a history of use or clinical features consistent 
with acute established illicit/recreational drug or NPS 
toxicity, or if they relate to misuse of a prescription/
over-the-counter medicine.
Exclusion criteria: Presentations are excluded if they 
are not directly related to acute recreational drug 
toxicity (for example, trauma, infection or drug 
withdrawal) or are the result of self-harm. Cases of 
lone alcohol intoxication are also excluded, but data 
on whether or not alcohol is co-used with a drug/NPS 
is collected.
Case definition
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FIGURE 1
Geographical location of the Euro-DEN Plus centres
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Each centre collects the data from information recorded in 
the medical records and returns the Euro-DEN data 
collection sheets to the lead centre at Guy’s and St Thomas’ 
NHS Foundation Trust in London for collation and further 
analysis.
I  Euro-DEN Plus two-year dataset: overview of the current situation
I Description of the presentations 
There were 10 956 presentations to the 16 original sentinel 
Euro-DEN centres over the two-year period between 
October 2013 and September 2015, with 5 529 of these 
presentations between October 2013 and September 
2014 and 5 427 between October 2014 and September 
2015. As shown in Figures 2 and 3, there were variations in 
the number of presentations per centre, with the greatest 
number to the Oslo Accident and Emergency Outpatient 
Clinic (OAEOC) and London St Thomas’ Hospital (STH) 
centres (Figure 2). A total of 70.2 % of the Euro-DEN Plus 
presentations were to five of the 16 centres (Oslo OAEOC, 
London STH, Dublin, London King’s College Hospital (KCH) 
and Paris) and 60.7 % were in two of the 10 countries 
(Norway and the United Kingdom) (Figure 3). For the 11 
centres for which data were available for both years, 
Euro-DEN Plus presentations were a median of  
0.5 % (IQR 0.2–1.1 %, range 0.1–2.8 %) of all emergency 
department presentations over the two-year period.
Overall, there were a similar number of presentations to 
the Euro-DEN Plus centres in year 1 (5 529) and year 2  
(5 427). Although the number of Euro-DEN Plus 
presentations remained relatively stable over the two-year 
collection period in six centres, five centres had an 
increase of more than 10 % in the number of presentations 
between year 1 and year 2 and five had a decrease of more 
than 10 % (Figure 2).
Overall, 68.5 % of presentations arrived at the emergency 
department by ambulance, indicating significant utilisation 
of pre-hospital emergency services and associated 
resources.
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FIGURE 2
Number of Euro-DEN presentations per centre for year 1 and year 2
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Demographics 
There was a predominance of males amongst the 
presentations at all ages, and 76.0 % of all Euro-DEN 
Plus presentations over the two-year period were in 
males (Figure 4). Presentations were most common 
among those aged 20–39 (65.8 % of presentations); the 
median (inter-quartile range (IQR)) age was 31 (24–39) 
years, with a range from 11 to 90 years old.
Place of residence 
Data on the place of residence for each presentation were 
collected during the first year of the project (October 2013 
to September 2014). Across all of the centres, 73.9 % of 
individuals were resident in the city at which they 
presented, 19.5 % were resident in another city in that 
country and 3.6 % were from another country (place of 
residence was unknown or not recorded in 2.8 % of 
presentations). There was some variation between the 
centres in relation to the proportion of presentations that 
were classified as ‘local residents’ of the city in which they 
presented, from more than 90 % in Paris, Pärnu and York to 
less than 70 % in Barcelona, Gdańsk, Munich, Oslo OAEOC 
and Oslo Ullevål.
FIGURE 3
Trends in number of Euro-DEN presentations per centre for year 1 and year 2, from October 2013 to September 2015
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Age and gender profile of the presentations to the  
Euro-DEN centres from October 2013 to September 2015 
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Time patterns in the presentations 
There appears to be a seasonal variation in presentations, 
with fewer presentations in the winter months (December, 
January and February) compared to the summer months 
(June, July and August) (Figure 3). Analysis of the 5 529 
presentations over the first year between October 2013 
and September 2014 showed that there was a greater 
proportion of presentations per day at the weekend (18.4 % 
and 17.4 % of presentations occurred on a Saturday and 
Sunday respectively) compared to other days of the week 
(12.1 % to 13.4 % occurred per day from Monday to Friday). 
Presentations were also more common in the evening and 
early hours of the morning than during ‘core’ working hours 
— more than 4.5 % of presentations per hour from 17:00 to 
04:00 and fewer than 4.0 % from 04:00 to 15:00 (Figure 5).
I Drugs involved in the presentations 
A total of 16 986 drugs (excluding alcohol) were involved 
in the 10 956 presentations, which is a mean ± SD of 1.55 
± 0.73 drugs per presentation. The majority of presentations 
involved one (61.9 %) or two (26.0 %) drugs and only 3.5 % 
FIGURE 5
Percentage of presentations to the Euro-DEN centres,  
by time of day (year 1, October 2013 to September 2014)
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involved four or more drugs. Whether or not alcohol was 
involved in the presentation was not recorded in 3.8 % of 
presentations; where it was recorded, alcohol was used 
in 61.7 % of presentations and not used in 38.3 % of 
presentations.
Drug categories 
The drugs involved in the presentations were 
predominantly established illicit drugs (64.3 % of drugs)  
or prescription/over-the-counter (OTC) medicines  
(25.5 % of drugs) (Figure 6).
Over the two-year period, 7.0 % of drugs involved in the 
presentations were NPS. There was an increase in 
presentations involving an NPS, from 5.6 % of reported 
drugs in year 1 (October 2013 to September 2014) to  
8.5 % in year 2 (October 2014 to September 2015).
Analysis of biological samples for detection of the drug(s) 
used was undertaken as part of routine clinical care in  
15.6 % of presentations, and predominately this was by 
immunoassay without confirmatory high-pressure liquid 
chromatography (HPLC), gas chromatography–mass 
spectrometry (GC-MS) or liquid chromatography–tandem 
mass spectrometry (LC-MSMS).
FIGURE 6
Drug categories reported by the Euro-DEN centres in  
year 1 and year 2
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Top 20 drugs 
The top 20 most commonly reported drugs and the relative 
change between the two years are shown in Figure 7. 
Nineteen drugs were in the top 20 in both years; 
methedrone was number 19 in year 1 but had dropped to 
number 23 in year 2, and zopiclone was number 21 in  
year 1 and had risen to number 15 in year 2. The most 
commonly reported illicit drug, NPS and prescription 
medicine were: heroin (number 1), mephedrone  
(number 8) and clonazepam (number 7).
There is geographical variation in the drugs involved in the 
Euro-DEN presentations — one example of this is GHB/GBL, 
which was involved in more than 20 % of presentations in 
four centres (the two London centres, Oslo Ullevål and 
Barcelona) but in contrast was involved in less than 2 % of 
presentations in six centres (Gdańsk, Basel, Dublin, 
Mallorca, Drogheda and York). The geographical variation 
reflects the diversity of the populations served, the 
availability of drugs/NPS in each country and the local 
pattern/prevalence of use of these drugs/NPS in the areas 
covered by the sentinel centres.
I Clinical features 
Data are collected for all Euro-DEN Plus presentations on 
whether or not individuals develop 14 predetermined 
clinical features during their hospital stay (Wood et al., 
2014). The proportion of presentations that developed 
these features and the proportion that had tachycardia 
and coma at presentation are shown in Figure 8.
Overall, 38.1 % did not develop any of these clinical 
features. The most commonly reported clinical feature was 
agitation/aggression, which was recorded in 25.8 % of the 
presentations. A clinically significant minority also had 
other severe clinical features, including chest pain (6.6 % 
of presentations), psychosis (6.1 %), seizures (3.5 %) and 
hyperthermia (temperature ≥ 39 °C, 1.4 %). Furthermore, 
FIGURE 7
Top 20 drugs (16 986 drugs in 10 956 presentations) reported by the Euro-DEN centres from October 2013 to 
September 2015
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deaths were males and the median age was 29 (IQR 
29–39, range 18–53 years). Twenty-three of the deaths 
occurred within the emergency department and 26 deaths 
occurred after admission to hospital; 22 of these deaths 
occurred 24 hours or more after hospital presentation.
The most common drugs involved in the deaths were 
opioids (23 deaths: 12 heroin and 11 other opioids) and/or 
stimulants (15 deaths; most commonly involving cocaine, 
amphetamine, mephedrone and MDMA). NPS were 
involved in nine deaths and the most common NPS 
involved was mephedrone, which was involved in four 
deaths.
I Drug profiles 
The overall characteristics of those presenting during year 1 
of the Euro-DEN project with problems related to the use 
of the top three established illicit drugs (heroin, cocaine, 
cannabis) and the most common NPS mephedrone, where 
no other drug was reported to have been used, are profiled 
in more detail in Figure 11. This summarises the 
demographics of users, most commonly reported place of 
use of the drug, clinical features and outcomes.
58 (0.5 %) patients arrived in the emergency department 
in cardiorespiratory arrest; of these 26 (45 %) survived to 
hospital discharge.
I Outcomes 
Discharge from the emergency department 
Over three-quarters of patients (75.7 %) were discharged 
directly from the emergency department, either medically 
discharged (58.5 %) or self-discharged (17.2 %) (Figure 9). 
Only a minority were admitted to hospital, with 5.7 % 
requiring admission to a critical care area and 4.2 % to  
a psychiatric ward.
Length of hospital stay 
The length of hospital stay is defined as from the time of 
presentation to the emergency department, to the time of 
discharge from the hospital. As shown in Figure 10, almost 
half (44.7 %) of the presentations were discharged from 
hospital within four hours of their presentation to the 
emergency department and only 10.6 % of presentations 
had a hospital stay of more than 24 hours. The overall 
median (IQR) length of stay from time of presentation to 
the emergency department to final hospital discharge was 
4 hours 36 minutes (2 hours 28 minutes to 9 hours 34 
minutes).
Deaths 
There were 49 deaths (deaths were recorded if they 
occurred after attendance at the emergency department 
and before discharge from hospital), giving an overall 
fatality rate of 0.4 %. Thirty-two (65 %) of the patients who 
died arrived in the emergency department in 
cardiorespiratory arrest. The majority (41; 84 %) of the 
FIGURE 9
Destination following discharge from the emergency 
department for the Euro-DEN presentations from  
October 2013 to September 2015
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FIGURE 10
Length of stay of the presentations to the Euro-DEN 
network from October 2013 to September 2015
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I  Limitations of the Euro-DEN sentinel network data 
There are limitations in the representativeness of the 
available Euro-DEN data, as sentinel centres have limited 
coverage locally (at a city level), and do not represent national 
data. They are not necessarily representative of other settings 
and reflect the catchment area and its problem drug use 
patterns. Only a minority of the cases have a laboratory 
toxicology confirmation so most of the data comes from the 
patient’s self-reports and the clinician’s judgement. However, 
this is in line with current international recommendations and 
practice in the management of presentations to emergency 
departments of individuals with acute drug toxicity. 
Nevertheless, these limitations are balanced by the 
systematic data collation for all presentations with acute drug 
toxicity to the sentinel centres. This is more sensitive and 
provides more comprehensive data compared to those 
automatically extracted from hospital databases (Shah et al., 
2011; Wood et al., 2011) and provides a unique insight into 
acute drug toxicity presentations in Europe, in the context 
of the current limited systematic collection of data in this 
area (Heyerdahl et al., 2014).
I  Further development of the network 
The data presented in this report are from the original Euro-
DEN network of 16 sentinel emergency departments in 10 
European countries. However, the Euro-DEN group 
recognises that, to enhance the European relevance of this 
dataset, further sentinel centres should be recruited — 
increasing both the number of countries involved and the 
number of centres per country. In light of this, the Euro-
DEN Plus group has continued to recruit new sentinel 
centres to increase both the geographical coverage across 
Europe (now 14 countries) and the number of specialist 
sentinel centres (now 20 centres; see Figure 1). The other 
recent change to the network is that the centre in Denmark 
moved from Copenhagen to Roskilde in January 2016.
Discussions are currently taking place to recruit new 
sentinel centres in three other countries. The group plans 
to focus on increasing the recruitment of new sentinel 
centres in the Baltic regions and Eastern Europe over the 
next two to three years.
FIGURE 11
Drug profiles for the Euro-DEN presentations involving heroin, cocaine, cannabis and mephedrone, when reported as the 
only drug (year 1: October 2013 to September 2014)
Cocaine (n=421)
Age of users: 30 (25–36) years 
Male users: 76.2 %
Presentations with alcohol: 61.0 %
Length of stay: 3:40 (2:00–8:14) hr:min
To critical care: 4.0 %
Fatal: 0.5 %
Top place of use: home
Common eects: anxiety, chest pain, 
palpitations, agitation
Heroin (n=662)
Age of users: 36 (29–45) years 
Male users: 81.9 %
Presentations with alcohol: 14.8 %
Length of stay: 4:59 (2:56–7:46) hr:min
To critical care: 3.9 %
Fatal: 0.9 %
Top place of use: street
Common eects: coma, low respiratory rate, 
agitation, hypotension
Mephedrone (n=88)
Age of users: 27 (24–33) years 
Male users: 68.2 %
Presentations with alcohol: 18.2 %
Length of stay: 3:45 (2:03–7:19) hr:min
To critical care: 2.3 %
Fatal: 1.1 %
Top place of use: home
Common eects: agitation, anxiety,
palpitations, chest pain
Cannabis (n=421)
Age of users: 24 (19–30) years 
Male users: 72.0 %
Presentations with alcohol: 48.7 %
Length of stay: 3:01 (1:49–5:24) hr:min
To critical care: 0.7 %
Fatal: 0.2 %
Top place of use: home
Common eects: anxiety, agitation, 
vomiting, palpitations
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I Snapshots 
In addition to the expansion of the sentinel centre network, 
the Euro-DEN group has been exploring other potential 
avenues to collect representative data on emergency 
department presentations with acute drug toxicity. One 
potential strategy is the use of ‘snapshots’ to identify and 
collect data on emergency department acute drug/NPS 
toxicity presentations over shorter periods of time in 
multiple centres. This would extend the coverage to 
countries and regions that are currently unrepresented. It is 
also possible that the data could be used in some cities to 
cross-check other local data sources, including wastewater 
monitoring (3).
The Euro-DEN Plus group has undertaken some modelling 
looking at cases in year 1 of the project to determine whether 
it would be possible to identify the optimum time period for 
snapshot sampling that was representative of the whole year 
data collection period. Initial review suggests that several of 
these snapshot periods and/or frequencies may provide 
reasonably representative data for demographics (age and 
gender), length of stay and discharge from the emergency 
department; critical care admissions were only representative 
when whole data was collected, reflecting the infrequent 
rate of admission to critical care. Using snapshots to identify 
the drugs involved in presentations was more dependent on 
the volume (number) of presentations to each centre and on 
the frequency of the individual drugs in that centre.
In conclusion, the snapshots appeared to provide fairly 
reliable data across all centres for ‘high frequency’ drugs (the 
top four to six in each centre, typically heroin, cannabis, 
cocaine, GHB, amphetamines), but with decreasing volume of 
presentations the representativeness decreased as the time 
period for the snapshot decreased. In relation to NPS, the 
snapshots might only provide reliable data for the most 
frequently reported NPS, mephedrone.
I  Highlights of the Euro-DEN Plus analysis 
The Euro-DEN Plus research group has started to undertake 
a number of specific analyses of the Euro-DEN and/or 
Euro-DEN Plus datasets to look in more detail at geographical, 
demographic, clinical and outcome parameters with a view to 
produce further evidence on the current state and trends in 
acute drug toxicity in Europe. This section summarises the 
main findings from some presentations at the meeting on 
(3)  See the EMCDDA’s Perspectives on drugs, Wastewater analysis and 
drugs — a European multi-city study, available from  
http://www.emcdda.europa.eu/topics/pods/waste-water-analysis
prescription medicines, benzodiazepines and Z drugs (4), 
the impact of the co-use of benzodiazepines on acute 
heroin toxicity, NPS and MDMA.
I Prescription medicine presentations
Of the 10 956 presentations in the Euro-DEN Plus dataset, 
approximately 29 % involved at least one prescription/OTC 
medicine, and of these 45 % involved only prescription 
medicines, with no illicit drugs or NPS. There was considerable 
variation between centres in the proportion of cases related 
only to prescription medicines, with less than 10 % of cases 
at seven centres, and more than 20 % at five centres.
The two drug groups most commonly involved in the 
prescription medicine presentations were 
benzodiazepines/Z-drugs and opioids. The results for 
benzodiazepines and Z-drugs are discussed in more detail in 
the next section. The most common named opioids involved 
were methadone and buprenorphine. The pattern of opioids 
involved in the presentations is significantly different from 
the pattern of opioids misused in the USA — there were no 
reports of hydrocodone or hydromorphone in Euro-DEN Plus 
presentations, and oxycodone was involved in only 14 (1.1 %) 
presentations involving a prescription opioid (of these 14 
presentations involving oxycodone, five involved only 
oxycodone with no illicit drug or NPS). (Source: A. Dines, 
presentation at the Euro-DEN Plus research group meeting.)
I  Benzodiazepines and Z-drugs: geographical variations across Europe 
An analysis of the 20 % of Euro-DEN presentations that 
involved the use of a benzodiazepine showed that the cohort 
who presented after use of a benzodiazepine was older 
(median (IQR) age 35 (28–44)) than the overall Euro-DEN 
Plus group (median age 31 (24–39)). The most commonly 
named benzodiazepines were clonazepam, diazepam and 
alprazolam; and the most common Z-drug was zopiclone. 
There was geographical variation in the most commonly 
reported benzodiazepine: clonazepam was common in 
Norway and Ireland; diazepam in the UK and Switzerland; 
alprazolam in Spain and Poland; and zopiclone in Denmark. 
The Euro-DEN Plus group is currently looking at whether 
comparison with other indicators such as prescribing or 
population level drug utilisation data, or drug user surveys, 
could be used to understand whether these patterns reflect 
differences in prescribing (and therefore availability), or user 
preferences in benzodiazepines that lead to those who are 
(4)  Z-drugs are a group of non-benzodiazepine drugs with effects similar to 
benzodiazepines, which are used in the treatment of insomnia and most 
of whose names start with the letter 'Z’ (e.g. zaleplon, zolpidem and 
zopiclone).
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using benzodiazepines seeking different drug(s) from 
alternative routes of supply. (Source: C. Yates, presentation 
at the Euro-DEN Plus research group meeting.)
I  The impact of co-use of benzodiazepines with heroin: a common choice for polydrug use 
Previous work on benzodiazepines at the EMCDDA, 
summarised in the 2015 Perspectives on drugs (5), has 
suggested that heroin users who co-used benzodiazepines 
have greater utilisation of emergency and non-emergency 
healthcare services and are at greater risk of heroin toxicity 
with poorer outcome following an overdose than those who 
had not co-used benzodiazepines. An analysis was carried 
out of the first year of the Euro-DEN dataset on the clinical 
features and outcomes in presentations associated with 
lone heroin use (662 presentations) compared to 
presentations in which there was reported combined use of 
heroin with benzodiazepines (163 presentations). Clinically 
significant features and outcomes (proportion with coma, 
requiring intubation for respiratory support and/or requiring 
critical care admission; and overall length of hospital stay) 
were no different between the lone heroin and heroin/
benzodiazepine groups. This suggests that co-use of 
benzodiazepines with heroin, in this cohort, was not 
associated with poorer clinical outcomes. Further work is 
required to understand whether this may be related to other 
factors, such as lower dose heroin use in those co-using  
a benzodiazepine. (Source: D. M. Wood and T. Yamamoto, 
presentation at the Euro-DEN Plus research group meeting.)
I  NPS: mainly cathinones but synthetic cannabinoid receptor agonists (SCRAs) are increasing 
Over the last decade there has been increasing detection of 
NPS, with 98 new compounds detected in Europe in 2015 
and a total of 560 NPS currently being monitored by the 
European Early Warning System at the EMCDDA (EMCDDA, 
2016a; EMCDDA and Europol, 2016). One of the challenges 
in the risk assessment of NPS is the limited availability of 
data on the epidemiology of use and harms associated with 
the use of NPS in Europe. Euro-DEN Plus provides a valuable 
insight into acute NPS presentations in a large European 
cohort with acute drug toxicity. Approximately 7 % of cases 
in the two-year Euro-DEN Plus dataset involved the use of 
an NPS. There was a distinct geographical distribution of 
cases, with more than 10 % of cases involving an NPS seen 
in the UK (London STH, London KCH and York), Germany 
(Munich), Ireland (Dublin) and Poland (Gdańsk)
(5)  See the EMCDDA’s Perspectives on drugs, The misuse of benzodiazepines 
among high-risk opioid users in Europe, available from  
http://www.emcdda.europa.eu/topics/pods/benzodiazepines
.The largest class of NPS seen were the cathinones, in almost 
two-thirds of cases involving an NPS. There was a significant 
increase in the number of cases involving synthetic 
cannabinoid receptor agonists (SCRAs) and ‘branded’ 
products between year 1 (October 2013 to September 
2014) and year 2 (October 2014 to September 2015). The 
most frequently reported single NPS was the cathinone 
mephedrone (554 cases, representing almost three-
quarters of the cathinone presentations). The clinical 
features seen in the Euro-DEN Plus mephedrone cases 
were similar to those reported in other published datasets 
of acute mephedrone toxicity (EMCDDA, 2011). This 
suggests that the information being collected from self-
reported use of NPS in the Euro-DEN Plus dataset is 
comparable to other datasets, including those with 
analytical confirmation, and provides validity for the 
Euro-DEN Plus method of collection of data on acute NPS 
toxicity. Future analysis of the Euro-DEN Plus NPS cohort 
will concentrate on the geographical pattern of 
presentations, and as the Euro-DEN Plus dataset grows it 
will enable description of the patterns of acute toxicity 
associated with individual NPS and NPS classes. (Source: 
D.M. Wood, presentation at the Euro-DEN Plus research 
group meeting.)
I Focus on MDMA presentations
In October 2015 the EMCDDA held an expert meeting as  
a component in a study that explored changes in the 
availability and purity of MDMA (‘ecstasy’) together with 
reports of increasing use, harm and deaths associated with 
ecstasy around Europe (EMCDDA, 2016b). Euro-DEN 
provided input into the study with an analysis of Euro-DEN 
Plus cases involving MDMA over the 15-month period 
between October 2013 and December 2014. Over this time 
period there were 549 Euro-DEN Plus presentations 
involving MDMA — this represented 8 % of all Euro-DEN 
presentations; there were no reported cases involving PMA 
(para-methoxyamphetamine) or PMMA (para-methoxy-N-
methylamphetamine). There was geographical variation in 
the proportion of cases in which MDMA was involved — 
from over 10 % in five centres (Basel, Copenhagen, 
Drogheda, London STH, London KCH) to less than 5 % in 
seven centres (Barcelona, Gdańsk, Munich, Oslo OAEOC, 
Oslo Ullevål, Pärnu and Tallinn). There was no difference in 
the proportion of cases involving MDMA from October to 
December 2013 (9.1 %) and from October to December 
2014 (7.2 %). Clinical features were consistent with acute 
stimulant/sympathomimetic toxicity (common features 
included agitation/aggression in 32 %, tachycardia at 
presentation (≥ 120 bpm) in 23 %, palpitations in 13 %, 
chest pain in 10 % and seizures in 7 %). Hyperpyrexia 
(temperature ≥ 39°C) was seen in only 3 % of presentations 
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but when present, this was associated with poorer clinical 
outcomes (longer length of stay, admission to critical care) 
and both of the deaths were in individuals who developed 
hyperpyrexia. (Source: P. I. Dargan, C. Lyphout, J. Mounteney 
and I. Giraudon, presentation at the Euro-DEN Plus research 
group meeting.)
I Brief interventions 
The recent EMCDDA review on the effectiveness of brief 
interventions (6) in patients presenting to emergency 
departments with substance-related problems showed that 
by 2015 there had been five systematic reviews and 14 
randomised controlled trials of brief interventions in these 
settings (EMCDDA, 2016c). The majority related to alcohol, 
and only four randomised controlled trials focused on illicit 
drugs (three focused on drug use and one included 
individuals with substance use in general). A variety of brief 
interventions were used in these four studies, delivered by 
a range of healthcare professionals, with differing outcome 
measures. The studies reported that the emergency 
department provided a unique setting for delivering brief 
interventions for both illicit drugs and alcohol. Although 
there were potential benefits from brief interventions in 
terms of behavioural changes, the heterogeneity of the 
studies means the results are not more widely 
generalisable. It is also important to recognise the balance, 
in busy emergency departments, between providing acute 
medical care for patients within the department and 
secondary outputs such as brief interventions. The Euro-
DEN Plus steering group will be investigating the expansion 
of its work projects to include an evaluation of brief 
interventions in emergency department settings, in 
particular the feasibility of training general emergency 
department clinicians to deliver them. (Source: M. Ferri, 
presentation at the Euro-DEN Plus research group meeting.)
(6)  Brief interventions are psychosocial techniques designed to help 
recipients recognise harmful patterns of substance use, and to 
motivate and support them to address that use.
I Conclusions 
Data show that every year in Europe thousands of 
individuals suffer drug-related acute toxicity that 
requires some medical assistance. These drug-related 
hospital emergency presentations are most likely to 
occur in young adults, and, in the Euro-DEN sample at 
least, to involve heroin, cocaine and cannabis. Findings 
from the Euro-DEN Plus network also highlight the 
potentially considerable burden on health services and 
related costs. While most cases are discharged quickly, a 
small but significant proportion develops severe acute 
toxicity requiring critical care admission and there are 
some deaths amongst this cohort.
Data from hospital emergency department presentations 
provide a unique insight into acute health harms related 
to drug use, complementing other key indicator data and 
broadening the scope and potential impact of monitoring 
the health consequences of drug use. Findings from the 
Euro-DEN Plus project help to increase understanding of 
the drugs responsible for acute toxicity in Europe, 
whether they are illicit substances, misused prescription 
medicines or NPS. This dataset also enables analysis of 
geographical and time trends, patterns of acute toxicity 
and the potential implications of these presentations. 
While the data do not necessarily provide a nationally 
representative picture, as only selected sites are 
included from participating countries, using a number of 
sentinel sites in significant locations provides useful 
information on the kinds of drugs impacting on 
presentations to emergency services in Europe and the 
trends in these sites.
Continuation and further development of work in this 
area is important to enable a greater understanding of 
the acute harm associated with the use of a range of 
substances in Europe. This will help to inform delivery of 
appropriate healthcare and prevention activities, enable 
a better understanding of the patterns of toxicity 
associated with drug use, ensure that policy is informed 
by evidence of the harms these drugs cause and provide 
input into risk assessment of NPS.
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